Oeso held its first clinical study on esophageal squamous carcinoma in China

From November 7 to 9, the 15th World Congress of esophageal diseases (oeso) was held in China for the first time Researchers and clinical workers from more than 100 countries all over the world attended the meeting to discuss and exchange the research progress and new trends of clinical treatment of esophageal diseases As one of the most authoritative and oldest international conferences in the field of esophageal diseases, oeso international conference was held in China for the first time, which means that the research achievements of esophageal diseases in China have gained international attention and recognition During the meeting, the first randomized, phase III clinical study (escort study) with the largest sample size of esophageal squamous carcinoma in China was selected as an oral report Professor Xu Jianming from the fifth medical center of the General Hospital of the people's Liberation Army and Professor Huang Jing from the Cancer Hospital of the Chinese Academy of Medical Sciences served as the main researchers The study was designed for Chinese patients with esophageal squamous carcinoma and achieved breakthrough positive results It is expected to open a new course of immunotherapy for esophageal squamous cell carcinoma It is reported that China has always been a major country in the incidence of esophageal cancer (ESCC), and the number of patients accounts for more than half of the world According to the cancer related data released by the National Cancer Center in 2019, the mortality of esophageal cancer in China ranks the fourth only after lung cancer, liver cancer and gastric cancer In addition to smoking, drinking and other bad habits, the incidence of esophageal cancer in China is mostly related to family history, malnutrition and eating foods containing nitrosamines, and there are obvious regional differences The early symptoms of esophageal cancer are often ignored by the public When patients show obvious disease symptoms, such as dysphagia, and then go to the hospital for examination, they often have developed into the late stage of cancer, and the difficulty of disease treatment is greatly increased " At present, chemotherapy is still the main treatment for esophageal cancer, but the effect of chemotherapy is not satisfactory According to statistics, the objective effective rate of late patients receiving chemotherapy is only 40% - 60%, and after the failure of first-line treatment, the median total survival time (MOS) is only 5-10 months, but there is no standard effective method for second-line treatment According to the data of several published studies on PD-1 monoclonal antibody in esophageal cancer, the effectiveness of immunotherapy for esophageal cancer is significantly better than that of chemotherapy, but not all the clinical research results are applicable and meet the actual treatment needs of patients in our country due to the population-specific segregation Escort study is a randomized controlled study only for patients with advanced esophageal squamous carcinoma in China Before this study, there was no immunotherapy study specifically designed for patients with esophageal squamous carcinoma in China In order to provide a treatment plan that meets the clinical needs of China, Chinese scientists selected 448 patients in the treatment group and the control group randomly by optimizing the top-level design of the escort study, 228 of them received the treatment of carrizumab, which is the third phase randomized study of PD-1 inhibitor treatment of esophageal squamous cell carcinoma in China.